

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION (June 24, 2003) (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2685.2046-003	APPLICATION NO.
		APPLICANT Richard P. Batycky	
		FILING DATE	CONFIRMATION NO.
			GROUP

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
JKM	AA	4,352,789	10-05-1982	Thiel
JKM	AB	4,959,358	09-25-1990	Carey et al.
JKM	AC	5,002,973	03-26-1991	Zeleznick et al.
JKM	AD	5,049,389	09-17-1991	Radhakrishnan
JKM	AE	5,655,523	08-12-1997	Hodson et al.
JKM	AF	5,738,865	04-14-1998	Baichwal et al.
JKM	AG	5,770,559	06-23-1998	Manning et al.
JKM	AH	6,076,522	06-20-2000	Dwivedi et al.
JKM	AJ	6,098,619	08-08-2000	Britto et al.
JKM	AJ	6,119,688	09-18-2000	Whaley et al.
JKM	AK	6,126,919	10-03-2000	Stefely et al.
JKM	AA2	6,183,782 B1	02-06-2001	Hallworth
JKM	AB2	6,221,398 B1	04-24-2001	Jakupovic et al.
JKM	AC2	6,245,339 B1	06-12-2001	Van Oort et al.
JKM	AD2	6,284,287 B1	09-04-2001	Sarlikiotis et al.
JKM	AE2	6,309,671 B1	10-30-2001	Foster et al.
JKM	AF2	6,360,743 B1	03-26-02	Andersson et al.
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER 	DATE CONSIDERED 8/26/05
---	----------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION (June 24, 2003) (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2685.2046-003	APPLICATION NO.
		APPLICANT Richard P. Batycky	
		FILING DATE	CONFIRMATION NO.
			GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
<i>Simons</i>	AR	Simons, F. E.R. et al., "Can Epinephrine Inhalations Be Substituted for Epinephrine Injection in Children at Risk for Systemic Anaphylaxis?" <i>Pediatrics</i> 106(5):1040-1044 (2000).	
<i>Gu</i>	AS	Gu, X. et al., "Epinephrine Absorption after Different Routes of Administration in an Animal Model," <i>Biopharm. Drug Dispos.</i> 20:401-405 (1999).	
<i>Heilborn</i>	AT	Heilborn, H. et al, "Comparison of subcutaneous injection and high-dose inhalation of epinephrine - Implications for self-treatment to prevent anaphylaxis," <i>J. Allergy Clin. Immunol</i> 78(6):1174-1179 (1986).	
<i>Warren</i>	AU	Warren, J.B. et al., "Systemic absorption of inhaled epinephrine," <i>Clin. Pharmacol. Ther.</i> 40(6):673-678 (1986).	
<i>Mellem</i>	AV	Mellem, H. et al., "Faster and more reliable absorption of adrenaline by aerosol inhalation than by subcutaneous injection," <i>Br. J. Clin. Pharmac.</i> 31:677-681 (1991).	
<i>Dahlof</i>	AW	Dahlof, C. et al., "Systemic absorption of adrenaline after aerosol, eye-drop and subcutaneous administration to healthy volunteers," <i>Allergy</i> 42:215-221 (1987).	
<i>Plomley</i>	AX	Plomley, R.F. and D. Czarny, "Inhaled adrenaline in the treatment of anaphylaxis," <i>Med. J. Aust.</i> 149:564 (1988).	
<i>Bullock</i>	AY	Bullock, K. And J.W. Lightbown, "The Spray-drying of Pharmaceutical Products, Part II. Certain Inorganic Salts," <i>The Chemist and Druggist</i> , CXL:147-148 (Jul-Dec 1943).	
<i>Bullock</i>	AZ	Bullock, K. et al., "The Spray-drying of Pharmaceutical Products, Part III. Digitalis, Adrenaline and Ascorbic Acid," <i>Year-book of Pharmacy XVI</i> :221-226 (1943).	
<i>EpiPen</i>	AR2	EpiPen® Autoinjector (Dey). Physicians' Desk Reference, 56 th ed. Montvale, New Jersey, Medical Economic Company, Inc. 2002:1236.	
<i>Simons</i>	AS2	Simons, F.E.R. et al.; "Epinephrine absorption in children with a history of anaphylaxis," <i>J. Allergy Clin. Immunol.</i> 101(1, part 1):33-37 (1998).	
<i>AAAI</i>	AT2	AAAI Board of Directors, Position Statement, "The use of epinephrine in the treatment of anaphylaxis," <i>J. Allergy Clin. Immunol.</i> 94(4):666-668 (1994).	
<i>Simons</i>	AU2	Simons, F.E.R., et al., "Epinephrine absorption in adults: Intramuscular versus subcutaneous injection," <i>J. Allergy Clin. Immunol.</i> 108(5):871-873 (2001).	

EXAMINER <i>James T. Mohr, Jr.</i>	DATE CONSIDERED 8/30/05
---------------------------------------	----------------------------


PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2685.2046-003	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Richard P. Batycky	
(June 24, 2003)		FILING DATE	CONFIRMATION NO.
(Use several sheets if necessary)			GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
JHR	AV2	Goldberg, A. and R. Confino-Cohen, "Insect sting-inflicted systemic reactions: Attitudes of patients with insect venom allergy regarding after-sting behavior and proper administration of epinephrine," <i>J. Allergy Clin. Immunol.</i> 106(6):1184-1189 (2000).	
JHR	AW2	Korenblat, P. et al., "A Retrospective Study of Epinephrine Administration for Anaphylaxis: How Many Doses Are Needed?" <i>Allergy and Asthma Proc.</i> 20(6):383-386 (1999).	
JHR	AX2	Sampson, H.A. et al., "Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents," <i>New Engl. J. Med.</i> 327:380-384 (1992).	
JHR	AY2	Neugut, A.I., et al., "Anaphylaxis in the United States, An Investigation Into Its Epidemiology," <i>Arch. Intern. Med.</i> 161:15-21 (2001).	
JHR	AZ2	Schwartz, H.J., et al., "Is unrecognized anaphylaxis a cause of sudden unexpected death?", <i>Clin. Exp. Allergy</i> , 25(9):866-870 (1995).	
JHR	AR3	Barnard, J.H., "Studies of 400 Hymenoptera sting deaths in the United States," <i>J. Allergy Clin. Immunol.</i> , 58(5):259-264 (1973).	
JHR	AS3	Kemp, S.F. et al., "Anaaphylaxis, A Review of 266 Cases," <i>Arch. Intern. Med.</i> 155:1749-1754 (1995).	
JHR	AT3	Pumphrey, R.S.H., "Lessons for management of anaphylaxis from a study of fatal reactions," <i>Clin. Exp. Allergy</i> , 30:1144-1150 (2000).	
JHR	AU3	Kaliner, M., "Allergy care in the next millennium: Guidelines for the specialty," <i>J. Allergy Clin. Immunol.</i> 99(6, pt1):729-734 (1997).	
JHR	AV3	Yunginger, J.W. et al., "Fatal Food-Induced Anaphylaxis," <i>JAMA</i> , 260(10):1450-1452 (1988).	
JHR	AW3	Atkinson, T. P. And M.A. Kaliner, "Anaphylaxis," <i>Med. Clin. North Am.</i> 74(4):841-855 (1992).	
JHR	AX3	McConachie, I. "Anaesthetic dilemmas. Laryngeal oedema following anaphylactic shock," <i>Br. J. Hosp. Med.</i> 47(3):201 (1992).	
JHR	AY3	Darbar, D. et al., "Epinephrine-Induced Changes in Serum Potassium and Cardiac Repolarization and Effects of Pretreatment With Propranolol and Diltiazem," <i>Am. J. Cardiol.</i> 77:1351-1355 (1996).	


EXAMINER 	DATE CONSIDERED 8/30/2005
---	------------------------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2685.2046-003	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Richard P. Batycky		
(June 24, 2003)		FILING DATE	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
Z3	Barnes, P.J., "Effect of β -agonists on inflammatory cells," <i>J. Allergy Clin. Immunol.</i> 104(2, pt 2):S10-S17 (1999).			
AR4	Bufarlni, A., et al., "Comparative Responses to Propofol Anaesthesia alone and with α_2 -Adrenergic Medications in a Canine Model," <i>Acta Vet. Scand.</i> 37(2):187-201 (1996).			
AS4	<i>British National Formulary</i> , 42:155-157 (Sep 2001).			
AT4	Medihaler-Epi (3M Health Care Limited). ABPI Compendium of Data Sheets and Summaries of Product Characteristics. 2 nd ed. London: Datapharm Publications Limited 693 (1998-1999).			
AU4	Soreide, E. et al., "Severe anaphylactic reactions outside hospital: etiology, symptoms and treatment," <i>Acta Anaesthesiol. Scand.</i> 32:339-342 (1988).			
AV4	National Advisory Committee on Immunization (NACI). "Anaphylaxis: Statement on Initial Management of in non-hospital settings," <i>Canada Communicable Disease Report</i> , 21-22:F1-F5 (1995).			
AW4	AAAAI Board of Directors, Position Statement, "Anaphylaxis in Schools and Other Child-care Settings," <i>J. Allergy Clin. Immunol.</i> 102(2):173-176 (1998).			
AX4	Scheuch, G. et al., "Measuring <i>in vivo</i> deposition of large porous particles," Abstract-138, ISAM, 12 th International Congress. <i>J. Aerosol. Med.</i> 12(2):127 (1999).			
AY4	Sabroe, R.A. et al., "Therapeutics, An audit of the use of self-administered adrenaline syringes in patients with angio-oedema," <i>British Assoc. Of Dermatology</i> 146:615-620 (2002).			
AZ4	Muller, U. et al., "Withdrawal of the Medihaler-epi®/Adrenaline Medihaler®: comments of the Subcommittee on Insect Venom Allergy of the EAACI," <i>Allergy</i> , 53:619-620 (1998).			
ARS	Primateine® Mist (Wyeth). Physicians' Desk Reference, 21th ed. Montvale, New Jersey, Medical Economic Company, Inc., 792 (2000).			

EXAMINER 	DATE CONSIDERED 01/30/2005
---	-------------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2685.2046-003	10/607,571
June 29, 2004 <i>(Use several sheets if necessary)</i>	APPLICANT	Richard P. Batycky <i>et al.</i>
	FILING DATE	CONFIRMATION NO.
	June 26, 2003	6287
		GROUP 3761



U.S. PATENT DOCUMENTS

EXAMINER 	DATE CONSIDERED 8/25/05
---	----------------------------

<p>PTO-1449 REPRODUCED</p> <p>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>June 29, 2004</p> <p><i>O I P E J C G</i> 4 2 2004</p> <p>Use several sheets if necessary)</p>	<p>ATTORNEY DOCKET NO. 2685.2046-003</p>	<p>APPLICATION NO. 10/607,571</p>
<p>APPLICANT</p> <p>Richard P. Batycky et al.</p>		
<p>FILING DATE</p> <p>June 26, 2003</p>		<p>CONFIRMATION NO.</p> <p>6287</p>
		<p>GROUP</p> <p>3761</p>



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER 	DATE CONSIDERED 8/25/2005
---	------------------------------